NASD · Healthcare · Biotechnology · USA
Erasca Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Erasca is a clinical-stage precision oncology company developing medicines targeting the RAS/MAPK pathway in cancer patients. The company's pipeline comprises two clinical-stage programs, ERAS-0015 and ERAS-4001, which are designed to inhibit RAS directly, along with ERAS-12, a discovery-stage EGFR antibody program.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Erasca Inc stock.
Not valued: We cannot value this company yet.
17 more funds hold it; the full list is part of the paid plan.
135 more in this industry show a wider margin of safety.
We do not publish a verdict on ERAS yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-10-19 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.